trending Market Intelligence /marketintelligence/en/news-insights/trending/6ijglb0z0hg4ffgslumdgq2 content esgSubNav
In This List

Endo secures injunction against QuVa Pharma over blood pressure therapy

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Endo secures injunction against QuVa Pharma over blood pressure therapy

Endo International plc obtained a preliminary injunction barring QuVa Pharma Inc. from selling a product that would compete with Endo's Vasostrict.

Endo subsidiaries Par Pharmaceutical Inc. and Par Sterile Products Inc. secured the preliminary injunction, which was issued by U.S. District Judge Brian Martinotti. The injunction is effective through the end of an as-yet unscheduled trial.

In its complaint, filed in the U.S. District Court for the District of New Jersey in August 2017, Par alleged that its trade secrets were misappropriated by QuVa and other defendants in relation to QuVa's development of a vasopressin product.

Endo's Vasostrict, a vasopressin injection, is used to increase blood pressure in adults with reduced blood pressure

Dublin's Endo International develops drugs for pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular diseases.